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Introduction {#bjs550219-sec-0006}
============

Trainee involvement in surgical procedures has been associated with benefit as well as adverse outcomes[1](#bjs550219-bib-0001){ref-type="ref"}, [2](#bjs550219-bib-0002){ref-type="ref"}, [3](#bjs550219-bib-0003){ref-type="ref"}, [4](#bjs550219-bib-0004){ref-type="ref"}. Studies have suggested that trainee involvement can result in improved colonic cancer detection rates at endoscopy[5](#bjs550219-bib-0005){ref-type="ref"}, lower bleeding complication rates in endocrine surgery[6](#bjs550219-bib-0006){ref-type="ref"}, and lower morbidity levels at teaching hospitals compared with non‐teaching hospitals[7](#bjs550219-bib-0007){ref-type="ref"}. Other studies[1](#bjs550219-bib-0001){ref-type="ref"}, [8](#bjs550219-bib-0008){ref-type="ref"}, however, have suggested that trainee involvement may be detrimental. A recent study[9](#bjs550219-bib-0009){ref-type="ref"} has suggested that the grade of trainee may be an important factor, with senior trainee involvement associated with poorer outcomes. Two studies[10](#bjs550219-bib-0010){ref-type="ref"}, [11](#bjs550219-bib-0011){ref-type="ref"} of trainee involvement in oesophagectomy, where trainees were likely to be senior, demonstrated no adverse impact on outcomes.

Changes in working patterns for trainees in many countries have meant increasing pressures on time available for training, and a shift towards achieving 'competency'[12](#bjs550219-bib-0012){ref-type="ref"}, [13](#bjs550219-bib-0013){ref-type="ref"}. Although the aim of these changes was to improve working conditions for surgical trainees, the potential adverse impact of reduction in hours is to reduce operative experience. Therefore, the challenge to provide excellent and evidence‐based patient‐centred care, while maintaining a viable surgical training programme, has become an important challenge in the face of decreasing training hours[14](#bjs550219-bib-0014){ref-type="ref"}, [15](#bjs550219-bib-0015){ref-type="ref"}.

Radical gastrectomy with systematic lymphadenectomy (often referred to as D2 gastrectomy) for adenocarcinoma of the stomach is a technically demanding operation associated with significant morbidity[16](#bjs550219-bib-0016){ref-type="ref"}. A recent study[17](#bjs550219-bib-0017){ref-type="ref"} demonstrated that the current level of active exposure of surgical trainees to laparoscopic gastric surgery for gastric cancer may be insufficient. Two other studies[18](#bjs550219-bib-0018){ref-type="ref"}, [19](#bjs550219-bib-0019){ref-type="ref"} indicated that less than 30 per cent of laparoscopic gastrectomies are carried out by trainees. Both studies demonstrated similar blood loss, lymph node harvest and short‐term morbidity between trainees and trainers as primary surgeons. In one of these studies[18](#bjs550219-bib-0018){ref-type="ref"}, trainees took longer to perform the procedure.

As there appear to be no published data on the impact of trainee involvement on outcomes, including long‐term survival, following open radical gastrectomy for adenocarcinoma, this study was undertaken to determine whether trainee involvement as the primary surgeon performing open D2 gastrectomies affected short‐ and long‐term surgical outcomes.

Methods {#bjs550219-sec-0007}
=======

A prospectively developed database of all patients undergoing a radical D2 open gastrectomy with curative intent for malignant disease was reviewed. Data from patients treated at a single centre (Northern Oesophago‐Gastric Unit, Newcastle upon Tyne, UK) between January 2009 and January 2014 were analysed. All patients were discussed by the multidisciplinary team following adequate staging investigations, and subsequently had an open total (TG) or subtotal (STG) gastrectomy with D2 lymphadenectomy, either as unimodality treatment or following neoadjuvant chemotherapy[20](#bjs550219-bib-0020){ref-type="ref"}.

Data including baseline demographics (age, sex, stage of disease, use of neoadjuvant treatment) were collected. Immediately after surgery, ASA grade, blood loss, duration of surgery, and grade of the primary surgeon and surgical assistants were recorded. Data collection was completed upon discharge, with details of final histology, stage of disease, lymph node yield, length of hospital stay and complications recorded. Data were entered by the consultant and trainee, and checked by an independent data manager. Complications were recorded and graded according to the Expanded Accordion Severity Classification of Postoperative Complications[21](#bjs550219-bib-0021){ref-type="ref"}. The UICC TNM (7th edition) staging system[22](#bjs550219-bib-0022){ref-type="ref"} was used for all patients.

Resections were carried out using a standard open approach with a radical *en bloc* D2 lymphadenectomy. Proximal tumours and patients diagnosed with diffuse‐type gastric cancers were treated by TG. STG was used for patients with a distal tumour where adequate clearance could be achieved. For both operations, resection and reconstruction phases were performed in an identical manner by consultants and trainees. TG involved an oesophagojejunal retrocolic stapled anastomosis fashioned with a circular stapling device, creating an end‐to‐side anastomosis. The small bowel end was closed with a stapler. Continuity with a 45‐cm Roux limb was created by a two‐layered continuous end‐to‐side handsewn anastomosis. For STG, the stomach was transected with a stapling device, the Roux limb was prepared as above, and an end‐to‐side gastrojejunostomy was created with a handsewn, two‐layered anastomosis.

Analysis {#bjs550219-sec-0008}
--------

Patients were divided into two cohorts according to whether a consultant or a trainee primarily performed the procedure. The trainee was regarded as being the primary surgeon if they performed more than 50 per cent of the operation. This would, in practice, mean that the trainee either performed all the steps described in the surgical technique section, or at least that the critical steps were performed by the trainee, such as the resection and lymphadenectomy. This was documented immediately after the operation, and agreed between trainer and trainee.

All documented complications were rechecked at monthly morbidity and mortality meetings to ensure a consensus on complication classification, and a final check was carried out by an independent data manager.

Statistical analysis {#bjs550219-sec-0009}
--------------------

Kruskal--Wallis and Mann--Whitney *U* tests were used to compare continuous variables, and categorical data were compared with χ^2^ or Fisher\'s exact test. Median (range) values are presented for descriptive data. The log rank (Mantel--Cox) test was used to compare survival between the groups. *P* \< 0·050 (two‐sided) was considered statistically significant. Statistical analysis was performed using SPSS® version 22.0 (IBM, Armonk, New York, USA).

Results {#bjs550219-sec-0010}
=======

Between January 2009 and January 2014, 167 patients underwent D2 STG and 105 had a TG. There were six consultants providing care and nine trainees, all of whom were within the last 3 years of training and had undertaken a median of 9 (range 0--35) malignant upper gastrointestinal resections before commencement of training at this institution.

Subtotal gastrectomy {#bjs550219-sec-0011}
--------------------

A total of 95 resections were performed by the six consultants and 72 by the nine trainees. No significant difference was observed in patient demographics, tumour histology, stage or ASA grade between the cohorts (*Table*  [1](#bjs550219-tbl-0001){ref-type="table"}). There was no difference between consultant and trainee cohorts in median duration of surgery (225 (range 150--580) *versus* 212 (125--380) min respectively; *P* = 0·192)*,* number of resected nodes (26 (5--103) *versus* 25 (1--63); *P* = 0·171) or length of hospital stay (10 (6--197) *versus* 14 (7--85) days; *P* = 0·242). However, there was lower median blood loss in the trainee cohort (235 (50--1000) ml *versus* 360 (50--3000) ml for consultants; *P* = 0·053). Major morbidity was significantly higher in the consultant cohort (12 per cent *versus* 4 per cent in the trainee cohort; *P* = 0·043). There was no significant difference in overall morbidity, or in the predicted 5‐year overall survival rate (70 per cent in the consultant cohort *versus* 75 per cent in the trainee cohort; *P* = 0·514).

###### 

Characteristics and outcomes of patients in the subtotal gastrectomy group

                                                                                  Consultant cohort (*n* = 95)   Trainee cohort (*n* = 72)   *P* [†](#bjs550219-note-0003){ref-type="fn"}
  ------------------------------------------------------------------------------ ------------------------------ --------------------------- -----------------------------------------------
  **Age (years)** [\*](#bjs550219-note-0002){ref-type="fn"}                               72 (24--90)                   74 (28--86)          0·166[‡](#bjs550219-note-0004){ref-type="fn"}
  **Sex ratio (M** : **F)**                                                                 57 : 38                       40 : 32                                0·189
  **Histology**                                                                                                                                                  0·821
  Adenocarcinoma                                                                               93                           70              
  Other                                                                                        2                             2              
  **Neoadjuvant therapy**                                                                                                                                        0·032
  None                                                                                      64 (67)                       58 (81)           
  Chemotherapy                                                                              31 (33)                       14 (19)           
  **Adjuvant therapy**                                                                                                                                           0·771
  None                                                                                      84 (88)                       63 (88)           
  Chemotherapy                                                                              11 (12)                       9 (12)            
  **BMI (kg/m** ^**2**^ **)** [\*](#bjs550219-note-0002){ref-type="fn"}                   26 (18--44)                  24·5 (17--39)         0·914[‡](#bjs550219-note-0004){ref-type="fn"}
  **ASA grade**                                                                                                                                                  0·354
  I                                                                                            6                             4              
  II                                                                                           45                           36              
  III                                                                                          41                           31              
  IV                                                                                           3                             1              
  **pT category**                                                                                                                                                0·832
  pT1                                                                                          23                           13              
  pT2                                                                                          14                           12              
  pT3                                                                                          32                           26              
  pT4                                                                                          24                           18              
  pTx (HGD)                                                                                    2                             3              
  **pN category**                                                                                                                                                0·954
  pN0                                                                                          41                           30              
  pN1                                                                                          23                           17              
  pN2                                                                                          17                           12              
  pN3                                                                                          14                           13              
  **Duration of surgery (min)** [\*](#bjs550219-note-0002){ref-type="fn"}                225 (150--580)               212 (125--380)         0·192[‡](#bjs550219-note-0004){ref-type="fn"}
  **No. of resected nodes** [\*](#bjs550219-note-0002){ref-type="fn"}                     26 (5--103)                   25 (1--63)           0·171[‡](#bjs550219-note-0004){ref-type="fn"}
  **Blood loss (ml)** [\*](#bjs550219-note-0002){ref-type="fn"}                          360 (50--3000)               235 (50--1000)         0·053[‡](#bjs550219-note-0004){ref-type="fn"}
  **Complications (all)**                                                                   32 (34)                       18 (25)                                0·113
  **Major complications (Accordion level ≥ 3)**                                             11 (12)                        3 (4)                                 0·043
  **In‐hospital mortality**                                                                    0                             0              
  **Length of hospital stay (days)** [\*](#bjs550219-note-0002){ref-type="fn"}            10 (6--197)                   14 (7--85)           0·242[‡](#bjs550219-note-0004){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are median (range). HGD, high‐grade dysplasia.

χ^2^ or Fisher\'s exact test, except

Kruskal--Wallis or Mann--Whitney *U* test.

Total gastrectomy {#bjs550219-sec-0012}
-----------------

A total of 54 resections were performed by the six consultants and 51 by the nine trainees.

No significant difference was noted in the demographics between the two cohorts (*Table*  [2](#bjs550219-tbl-0002){ref-type="table"}). Again, there was no significant difference between consultant and trainee cohorts in the operative outcome data with regard to median duration of surgery (240 (range 102--505) *versus* 240 (170--375) min respectively; *P* = 0·452), number of resected nodes (30 (13--101) *versus* 30 (11--102); *P* = 0·681) or length of hospital stay (15 (7--78) *versus* 15 (8--65) days; *P* = 0·981). The trainee cohort had a significantly lower median blood loss (360 (90--1200) ml *versus* 600 (70--2350) ml in the consultant cohort; *P* = 0·042). There was no significant difference in overall and major morbidity between the two cohorts, or in the predicted 5‐year overall survival rate (68 per cent in the consultant cohort *versus* 77 per cent in the trainee cohort; *P* = 0·254).

###### 

Characteristics and outcomes of patients in the total gastrectomy group

                                                                                  Consultant cohort (*n* = 54)   Trainee cohort (*n* = 51)   *P* [†](#bjs550219-note-0007){ref-type="fn"}
  ------------------------------------------------------------------------------ ------------------------------ --------------------------- -----------------------------------------------
  **Age (years)** [\*](#bjs550219-note-0006){ref-type="fn"}                               67 (41--81)                   72 (43--87)          0·062[‡](#bjs550219-note-0008){ref-type="fn"}
  **Sex ratio (M** : **F)**                                                                 41 : 13                       31 : 20                                0·464
  **Histology**                                                                                                                                                  0·054
  Adenocarcinoma                                                                               46                           50              
  Other                                                                                        8                             1              
  **Neoadjuvant therapy**                                                                                                                                        0·484
  None                                                                                      26 (48)                       29 (57)           
  Chemotherapy                                                                              28 (52)                       22 (43)           
  **Adjuvant therapy**                                                                                                                                           0·882
  None                                                                                      46 (85)                       43 (84)           
  Chemotherapy                                                                               8 (15)                       8 (16)            
  **BMI (kg/m** ^**2**^ **)** [\*](#bjs550219-note-0006){ref-type="fn"}                   27 (18--43)                   25 (20--46)          0·384[‡](#bjs550219-note-0008){ref-type="fn"}
  **ASA grade**                                                                                                                                                  0·474
  I                                                                                            2                             2              
  II                                                                                           38                           32              
  III                                                                                          14                           16              
  IV                                                                                           0                             1                                   0·343
  **pT category**                                                                                                                           
  pT1                                                                                          10                            8              
  pT2                                                                                          12                           15              
  pT3                                                                                          16                           20              
  pT4                                                                                          11                            7              
  pTx (HGD)                                                                                    5                             1              
  **pN category**                                                                                                                                                0·791
  pN0                                                                                          26                           23              
  pN1                                                                                          10                           13              
  pN2                                                                                          10                            7              
  pN3                                                                                          8                             8              
  **Duration of surgery (min)** [\*](#bjs550219-note-0006){ref-type="fn"}                240 (102--505)               240 (170--375)         0·452[‡](#bjs550219-note-0008){ref-type="fn"}
  **No. of resected nodes** [\*](#bjs550219-note-0006){ref-type="fn"}                     30 (13--101)                 30 (11--102)          0·681[‡](#bjs550219-note-0008){ref-type="fn"}
  **Blood loss (ml)** [\*](#bjs550219-note-0006){ref-type="fn"}                          600 (70--2350)               360 (90--1200)         0·042[‡](#bjs550219-note-0008){ref-type="fn"}
  **Complications (all)**                                                                   24 (44)                       25 (49)                                0·313
  **Major complications (Accordion level ≥ 3)**                                              8 (15)                       5 (10)                                 0·222
  **In‐hospital mortality**                                                                  2 (4)                         1 (2)                                 0·293
  **Length of hospital stay (days)** [\*](#bjs550219-note-0006){ref-type="fn"}             15 (7--78)                   15 (8--65)           0·981[‡](#bjs550219-note-0008){ref-type="fn"}

Values in parentheses are percentages unless indicated otherwise;

values are median (range). HGD, high‐grade dysplasia.

χ^2^ or Fisher\'s exact test, except

Kruskal--Wallis or Mann--Whitney *U* test.

Discussion {#bjs550219-sec-0013}
==========

This study showed that patient outcomes were not affected adversely by a supervised trainee performing a radical total or subtotal gastrectomy. Short‐ and long‐term outcomes were comparable between operations performed by consultants and trainees. The consultant cohort had greater blood loss for both procedures, and a higher rate of major complications in the STG cohort, although neither of these features affected length of hospital stay or predicted survival. A recent study[6](#bjs550219-bib-0006){ref-type="ref"} of more than 80 000 patients undergoing thyroid and parathyroid surgery demonstrated a decrease in the odds of bleeding complications in the trainee cohort. It is difficult to determine accurately the reasons for the discrepancy in blood loss in both operations, and also morbidity in the STG group. It may be that procedures in some patients, anticipated as being more difficult, were either consciously or subconsciously selected by trainers as less suitable for a trainee to perform. It is also possible that when a problem was encountered in a procedure initially undertaken by a trainee, the operation was taken over by a consultant. It was not possible to determine the number of occasions when this occurred, as no record was kept of any decision on who commenced a procedure and was intended to be the primary surgeon.

Previous studies have demonstrated higher rates of complications in emergency general surgical procedures undertaken by trainees[2](#bjs550219-bib-0002){ref-type="ref"}, as well as longer time taken by trainees to perform gastrectomies[18](#bjs550219-bib-0018){ref-type="ref"} and gastric bypass procedures[23](#bjs550219-bib-0023){ref-type="ref"}. The present study, however, demonstrated no inferiority in the rate of overall complications for both STG and TG, or in the duration of surgery between trainees and consultants. This finding is supported by previous work[11](#bjs550219-bib-0011){ref-type="ref"}, [24](#bjs550219-bib-0024){ref-type="ref"} in foregut surgery, including oesophageal, pancreatic and hepatic surgery, in which no compromise to patient outcomes was noted when a trainee was the primary surgeon. Other surgical specialties, including colorectal surgery, non‐oesophageal thoracic (lobectomies) and coronary artery bypass surgery, have also demonstrated non‐inferiority of outcomes when trainees or residents were the primary surgeons[25](#bjs550219-bib-0025){ref-type="ref"}, [26](#bjs550219-bib-0026){ref-type="ref"}, [27](#bjs550219-bib-0027){ref-type="ref"}.

A limitation of the study is its retrospective nature. It is not possible to determine how consultants decided which operations were suitable for trainees. In the absence of difference between the cohorts in ASA grade, BMI or stage of disease, it may be that trainers chose to perform the procedures they anticipated as being the most challenging. This may account for the greater blood loss in the trainer cohorts for both TG and STG.

Informed patient consent forms a fundamental part of the preoperative dialogue between surgeons and patients. Patients must be fully informed that a trainee may perform part or all of a procedure supervised. A previous study[28](#bjs550219-bib-0028){ref-type="ref"} suggested that as patients are made aware more explicitly of the involvement of trainees in a procedure, they are less likely to consent. The present study allows surgeons to provide evidence to patients that trainee involvement in a radical gastrectomy does not compromise short‐ or long‐term outcomes.
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